ANTIDOTE THERAPEUTICS, INC.
nicotine-degrading enzyme engineered with PEGylation for smoking cessation
- Sector
- Biotech
- Headquarters
- GAITHERSBURG, MD
- Founded
- 2013
- Latest Form D
- $200K, Sep 2017
- Total capital
- $833K
- Federal grants
- $201K
- 1 award · 2017
- Rank in peer group#361 of 392
- Private capital raised
- $632K
- 2 Form D · last Sep 2017
- 110 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 8 pending · first 2025
- Rank in peer group#70 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$200K
- Private capital raisedForm D · SEC · 1st filing$432K
- Federal grantHealth and Human S · Phase I · Protein Engineering of a Biologic Drug Candidate$201K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
6months
from ANTIDOTE THERAPEUTICS, INC.’s first federal award to its first private round.
- First federal award · Mar 2017
- Health and Human S · $201K
- First Form D · Sep 2017
- $432K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#70 · top 18%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Kenneth C. CarterDirectorNamed in SEC Form D filings
- Matthew W. Kalnik, PhDExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 9- GrantedNovel Nicotine Degrading Enzyme VariantsUSPTOUS 12,318,433
- PendingMethods For Improving Circulation And Treating Cardiovascular DiseaseUSPTOApplication 16972060
- PendingNicotine-degrading Enzymes For Treating Nicotine Addiction And Nicotine PoisoningUSPTOApplication 15749630
Show all 9 patent records
- Novel Nicotine Degrading Enzyme VariantsJun 3, 2025 · US 12,318,433Granted
- Methods For Improving Circulation And Treating Cardiovascular DiseaseAug 25, 2022 · Application 16972060Pending
- Nicotine-degrading Enzymes For Treating Nicotine Addiction And Nicotine PoisoningJan 17, 2019 · Application 15749630Pending
- Novel Nicotine-binding AntibodiesApplication PCTUS2018046621Pending
- Novel Nicotine Degrading Enzyme VariantsApplication 62713814Pending
- Methods For Improving Circulation And Treating Cardiovascular DiseaseApplication 62681342Pending
- Nicotine-degrading Enzymes For Treating Nicotine Addiction And Nicotine PoisoningApplication PCTUS2016045109Pending
- Novel Nicotine Degrading Enzyme VariantsApplication PCTUS2019040345Pending
- Methods For Improving Circulation And Treating Cardiovascular DiseaseApplication PCTUS2019035512Pending
Related companies, and why
- METANOIA BIO LLCSimilar federal contract value in Biotech · null in contracts
- THENDOR THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
- EPIVARIO INCSimilar federal contract value in Biotech · null in contracts
- Koutif Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- Biohaven Pharmaceutical Holding Co Ltd.Similar federal contract value in Biotech · null in contracts
- Ionetix CorpSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .